[Longterm intra-arterial infusion in the treatment of malignant tumors]. 1966

V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek

UI MeSH Term Description Entries
D007269 Injections, Intra-Arterial Delivery of drugs into an artery. Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000963 Antimetabolites Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) Antimetabolite

Related Publications

V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
February 1993, Journal of neuro-oncology,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
July 1965, New York state journal of medicine,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
August 1968, Nederlands tijdschrift voor geneeskunde,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
October 1969, Kangogaku zasshi,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
March 1969, La Radiologia medica,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
June 2022, Journal of neurointerventional surgery,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
January 1983, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
March 1964, Klinische Wochenschrift,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
September 1966, Seikeigeka. Orthopedic surgery,
V Vojtísek, and J Lorenc, and O Topol, and M Abrahamovic, and V Jelínek
October 1964, Jibi inkoka Otolaryngology,
Copied contents to your clipboard!